Deerfield Management Company, L.P. (Series C) Neurocrine Biosciences Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,489,000 shares of NBIX stock, worth $199 Million. This represents 4.17% of its overall portfolio holdings.
Number of Shares
1,489,000
Previous 862,000
72.74%
Holding current value
$199 Million
Previous $118 Million
39.96%
% of portfolio
4.17%
Previous 2.91%
Shares
13 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
96.9MCall Options Held
800KPut Options Held
565K-
Black Rock Inc. New York, NY14.2MShares$1.9 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.33 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$740 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$650 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$357 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...